An observational study in Stroke, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Zurich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Stroke by University of Zurich — 6 open to participants now, 8 under way, none of them phase 3. Stroke · University of Zurich.
Among the 26 studies in Stroke by University of Zurich, this one is the 11th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2019, is one of 13 observational ones, and was the 17th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →6 of the 26 studies in Stroke by University of Zurich are open now, in 1 country. Recruiting first, the newest first:
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Ages 18+ · Healthy volunteers
University of Zurich · Sites in Switzerland
Ages 18+
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 3
First in 2004; this study’s year is marked. 2 started in 2019.
This study's planned enrollment of 35 is below the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 49 across the 13 interventional studies, 98 across the 13 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
4 of the studies in Stroke by University of Zurich that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06466772University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT06534645University of ZurichSTOP-stroke: STroke Outcome Prediction in the Acute Treatment Setting | 2027-07-30 |
| NCT07534319University of ZurichInvestigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy | 2027-09-01 |
| NCT07056907University of ZurichEffects of Cerebrospinal Fluid Drainage on Cerebral Hemodynamics | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 26 studies in Stroke by University of Zurich, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to better understand the structural and functional changes that the CNS undergoes following stroke and how these changes relate to clinical measures. Both macroscopic and microscopic changes of the brain and the spinal cord will be examined in stroke patients and compared to healthy controls. In terms of structural plasticity, we aim to identify MR biomarkers that allow predicting the course of the patient's neurological status and accurately describe the course of the disease and the recovery. Importantly, we aim to investigate which factors scale the patients' symptoms.
In terms of functional plasticity, we will combine fMRI with behavioural motor and sensory testing to understand i) the structural and functional interplay between spinal and supraspinal neural circuits after stroke possibly driven by beneficial plasticity/regeneration vs. maladaptive plasticity/degeneration and ii) which clinical and behavioural determinants drive functional hand representations in the primary somatosensory and motor cortices to be maintained and which determinants drive reorganisation of functional representations following sensory input loss. We will further investigate the contribution of brainstem reorganisation to plasticity observed at the cortical level and, by doing so, aim to better understand the mechanistic underpinnings of functional reorganisation.
Patients with stroke and healthy subjects.
Inclusion Criteria - Patients:
Exclusion Criteria - Patients:
Inclusion Criteria - Healthy subjects:
Exclusion Criteria - Healthy subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: MRI
Diagnostic Test: MRI
We will examine chronic (\>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
Conventional magnetic resonance imaging (MRI) parameter
Structural characteristics in the brain and spinal cord are assessed in chronic stroke patients using conventional MRI and compared to healthy controls
Time frame: Up to 50 weeks]
Magnetic resonance spectroscopy (MRS) parameter
Metabolic parameter are assessed in chronic stroke patients using MRS in the brain and spinal cord and compared to healthy controls
Time frame: Up to 50 weeks
Functional MRI (fMRI) parameter
Brain activity or change of brain activities between 2 to 5 time points is assessed using fMRI during resting-state or a specific task in chronic stroke patients and compared to healthy controls
Time frame: Up to 50 weeks
Started Dec 2019 (actual). Primary completion is estimated for Jun 2028, 102 months after the start.
Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 102 months is above that.
Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jun 2027 → Jun 2028 and completion Jun 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.